Simon Property Group vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (90 vs 39)

Simon Property Group

EmergingReal Estate & Property Tech

General

Indianapolis largest US retail REIT (NYSE: SPG) at record $4.9B 2024 FFO; 96.5% occupancy (8-year high), $6.16B revenue, 232 properties/200M sq ft with Premium Outlets network competing with Macerich for luxury retail tenants.

AI VisibilityBeta
Overall Score
D39
Category Rank
#771 of 1167
AI Consensus
56%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
36
Gemini
34

About

Simon Property Group, Inc. is an Indianapolis, Indiana-based retail real estate investment trust — publicly traded on the New York Stock Exchange (NYSE: SPG) as an S&P 500 REIT component — owning or holding interests in 232 properties across 37 states and Puerto Rico plus 35 international properties, comprising 92 malls, 70 Premium Outlets, 14 Mills, 6 lifestyle centers, and 12 other retail properties totaling approximately 200 million square feet of retail space. In fiscal year 2024, Simon Property Group reported record total funds from operations (FFO) of $4.9 billion ($12.99 per share), trailing twelve-month revenue of $6.16 billion, domestic net operating income (NOI) growth of 4.7%, and portfolio occupancy of 96.5% — the highest in eight years — while signing a record 5,500 leases covering 21+ million square feet, with base minimum rent per square foot increasing 2.5% to $58.26. CEO David Simon (son of founder Melvin Simon, CEO since 1995, Chairman since 2007) has led the company through the pandemic retail disruption and the subsequent mall resurgence, emphasizing the "shop, eat, stay and play" mixed-use destination strategy. Founded in 1960 by Melvin Simon with two small strip malls near Indianapolis, Simon became the largest US REIT IPO in history at its $840 million IPO in 1993 and built its portfolio through acquisitions of DeBartolo Realty (1996), Chelsea Property Group ($3.5B, 2004), Mills Corporation (2007), and Taubman Centers ($3.4B, 2020).

Full profile

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A90
Category Rank
#9 of 1167
AI Consensus
60%
Trend
stable
Per Platform
ChatGPT
99
Perplexity
99
Gemini
83

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

39
Overall Score
90
#771
Category Rank
#9
56
AI Consensus
60
stable
Trend
stable
50
ChatGPT
99
36
Perplexity
99
34
Gemini
83
39
Claude
96
31
Grok
95

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.